cyrilzakka/clinical-trials huggingface dataset:
Clonidine Versus Adenosine to Treat Neuropathic Pain

The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.

This study is part of a pain center grant that focuses on how pain, especially chronic neuropathic pain, alters the response to traditional and non-traditional analgesics (pain medications).

Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.

Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.

Intrathecal clonidine relieves pain by actions on a2-adrenoceptors in the spinal cord, whereas adenosine relieves pain by actions on A1 adenosine receptors. Researchers believe that intrathecal adenosine and clonidine may prove to be excellent painkillers for nerve pain. Therefore, the goal of this study is to determine the effects of clonidine and adenosine on nerve pain.

After initial screening, baseline measurements, and training to learn to estimate pain accurately using thermal heat testing, a sample of spinal fluid will be taken from each participant. Participants then will be randomly chosen to receive either clonidine, adenosine, or placebo. After receiving the study medication, participants will be monitored, with their vital signs checked at 30, 60, 120, 180, and 240 minutes.

Duration of the study for participants is 2 weeks, and includes two visits to the research center, each lasting approximately 6 hours.

Eligibility Criteria:
Inclusion Criteria:

* Patients with complex regional pain syndrome (CRPS), type I involving a lower extremity

Exclusion Criteria:

* Pregnancy
* Allergy to clonidine
* Currently taking clonidine or other direct a2-adrenergic agonists, or taking cholinesterase inhibitors
* Patients with any serious or unstable medical problems (heart, lung, liver, kidney, or nervous system disease)
Brain Aging in Veterans (BRAVE) Training: A Cognitive Training Pilot Trial in Older Veterans With Traumatic Brain Injury

The purpose of this study is to conduct a pilot trial investigating cognitive training in older Veterans with a history of traumatic brain injury (TBI) to assess training effects, acceptability of training to participants, and to explore whether other factors influence training effects.

A study of older Veterans (60-85 years old) who have 1) a history of repetitive mild TBI or at least one moderate TBI and 2) subjective cognitive complaints. Participants will be randomized to one of three conditions for 4 weeks: Project:Evolution (EVO) multitask video game, EVO words video game, or an assessment only control condition. Participants will complete assessment visits at baseline, post-intervention (1 month after baseline), and 3 months post-intervention (4 months after baseline).

Eligibility Criteria:
Inclusion Criteria:

1. Ages 60-85
2. Have experienced more than one mild TBI or at least one moderate TBI over their lifetime
3. Have current cognitive problems based on self-report
4. Vision adequate to see test stimuli
5. Hearing adequate to understand the examiner
6. Fluent in English in order to understand task instructions
7. Demonstrate capacity to consent to participate in research
8. Mini-Mental Status Exam (MMSE) score ≥ 25

Exclusion Criteria:

1. History of penetrating brain injury
2. Active disabling neurological condition (e.g., stroke, brain tumor, multiple sclerosis)
3. History of severe psychiatric illness (i.e., schizophrenia, bipolar disorder, schizoaffective disorder)
4. Active drug use or active heavy alcohol use
5. History of severe TBI
6. History of a dementia diagnosis
7. Individuals who are physically unable to use an iPad for 30 minutes at a time per day will be excluded, such as individuals with debilitating arthritis or tremor
Cumulative Irritation Patch Test

A Cumulative Patch Test with a Challenge Phase is a test devised to ascertain if a chemical agent or agents have the potential to cause contact irritation or contact allergy in the skin. Allergy is only elicited in immunologically competent individuals who have become sensitized through exposure to the chemical agent at a sufficient concentration and for a sufficient duration of time.


Eligibility Criteria:
Inclusion Criteria:

* Subjects must not have any visible skin disease that might be confused with a skin reaction to the test trial;
* Subjects must not be participating in another clinical trial at this facility or any other facility;
* Subjects must be willing to avoid using topical or systemic steroids or antihistamines for at least 7 days prior to trial initiation and during the duration of the trial;
* Subjects must understand and execute and Informed Consent Form;
* Subjects must be capable of understanding and following directions;
* Subjects must be considered reliable;
* Subjects must be aged 16 to 79 years, inclusive;
* Subjects aged less than 18 years must have a parent or legal guardian execute the Informed Consent Form.

Exclusion Criteria:

* Subjects in ill health or taking medications, other than birth control, which could influence the purpose, integrity or outcome of the trial;
* Female subjects who report orally they are pregnant, planning to become pregnant or nursing during the course of the trial;
* Subjects who have a history of adverse reactions to adhesive tape, cosmetics, Over-The-Counter drugs or other personal care products;
* Subjects judged by the PI to be inappropriate for the trial.
Oral Chemotherapy and Quality of Care

PARCOURS is a non-interventional research study evaluating dysfunctions in the continuous city-hospital journey of a patients cohort treated by oral chemotherapy (60 patients followed for 3 months).

References used are the National Cancer Institute recommendations for the oral chemotherapy treated outpatients.

Parameters found are : information exchanged, ambulatory and hospital monitoring in case of adverse event and adherence to treatment. The study includes also a medico-economic evaluation (hospitalization and transport spending in case of dysfunction in the patient's journey). Deviations will be analyzed.


Eligibility Criteria:
Inclusion Criteria:

* Patient over 18 years old
* Suffering from cancer (hematological malignancies, digestive tumors, thoracic tumors or cutaneous tumors)
* With an oral anticancer chemotherapy initial prescription written by an oncologist or hematologist from the University Hospital of Caen, whatever the place of the drug dispensing (Community pharmacy or hospital pharmacy )

Exclusion Criteria:

- Patient treated by oral anticancer chemotherapy for another pathology
The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy

Membranous nephropathy (MN) may also be secondary to many other diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). In this study, the presence of Helicobacter Pylori (H. pylori) antigen was investigated in renal tissue from needle biopsy samples, and the prevalence of H. pylori infection and the effects of H. pylori eradication on proteinuria level in patients with MN will be investigated.

Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. It is thought to be mainly a primary or idiopathic form; however, it may also be secondary to many other diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). In this study, the presence of Helicobacter Pylori antigen was investigated in renal tissue from needle biopsy samples, and the prevalence of H. pylori infection and the effects of H. pylori eradication on proteinuria level in patients with MN will be investigated.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18-70 years
* Nondiabetic patients
* Patients with primary glomerulonephritis
* Clinical diagnosis of membranous nephropathy, IgA nephropathy or focal segmental glomerulosclerosis confirmed by biopsy
* Glomerular filtration rate \> 30 mL/min
* Patients who did not receive Helicobacter pylori eradication therapy within the last three months before enrollment in study

Exclusion Criteria:

* Patients with secondary glomerulonephritis
* Glomerular filtration rate \< 30 mL/min
* Patients who received Helicobacter pylori eradication therapy within the last three months before enrollment in study
* Patients with a history of gastric surgery
* Patients without an informed consent
ROUTE Registry Of the Utilisation of the Transaortic (Tao) TAVI Approach Using the Edwards Sapien XT Valve

This is an international multi-center, prospective, observational registry with consecutive patient enrollment intended to determine outcome Parameters within 30 days after transaortic transcatheter aortic valve replacement.

The purpose of this registry is to expand upon existing data sets, to identify patient characteristics and indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic stenosis that are undergoing transaortic transcatheter procedure with the commercially available Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ System.

Eligibility Criteria:
Inclusion Criteria:

* Intended transaortic (Tao) TAVI using Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ Delivery-System
* Compliance with the indications according to the Instructions for Use
* Written informed consent

Exclusion Criteria:

* Presence of contraindications as to the Instructions for Use
* TAo with concomitant procedure (e.g. Tao + CABG)
* Participation in the SOURCE XT registry
The Effects of Muscle Characteristics on the Control of Shoulder Complex During Functional Movements

The movement control of shoulder joint relies not only on the glenohumeral joint, but also the critical contributions from scapulothoracic joint. The relating scapula muscle strength, scapula mobility and, the most important of all, the capacity of neuromuscular control should be integrated into the rehabilitation program for patients with shoulder disorders. With regarding to the subacromial impingement syndrome or rotator tendinopathy, the status of scapula dyskinesia and dysfunctions were improved significantly after the intervention of scapula-emphasized exercise. But there was no study addressed the relationships between stiffness of relating muscles and the deficits of scapula movement. The stiffness had been shown to serve an important role in functional performance of the corresponding joint. For example, the decreased elasticity of supraspinatus muscle was noticed on affected side comparing in patients with impingement syndrome.Few studies examined the effects of altered muscle stiffness on kinematic performance in shoulder complex. Laudner et al. found that the stiffer the latismuss dorsi muscle was, the less upward rotation and posterior tilting, and the more internal rotation of scapula during arm elevation was exhibited in asymptomatic swimmers. Another study showed that the increased range of external rotation and posterior tilt of scapula during arm elevation were associated with the decreased stiffness of pectoralis minor. The recent study presented that the electromyographic activities and elasticities of middle deltoid, supraspinatus, and infraspinatus muscles correlated significantly with the tissue elasticity during shoulder movement in healthy shoulder. However, there was no scientific information directly to prove the changes in characteristics of rotator cuff function as well as the impacts on kinematic control of shoulder complex. Therefore, the aim of this study is to examine the relationship among characteristics of muscle properties and kinematic control healthy swimmers.


Eligibility Criteria:
Inclusion Criteria:

* freestyle swimmers with health shoulders

Exclusion Criteria:

* the past or current shoulder pain or disorders are examined by history taking and screening tests: shoulder impingement syndrome, instability, bony deformity, trauma, nerve injury or entrapment.
Firefighter Thermoregulatory Responses in Active Fire with Betaine Supplementation

The goal of this clinical trial is to compare betaine supplementation to placebo in firefighters undergoing live burn training regarding thermoregulation and inflammation. The main questions it aims to answer are:

* Does betaine supplementation mitigate rises in core temperature during firefighter live burn training?
* Does betaine supplementation decrease inflammation from firefighter training?
* Does betaine supplementation increase total body water stores?

Participants will supplement with betaine for 1 month and complete:

* Total Body Water measures
* Body Composition measures
* Live Burn training with Core Temperature Measurements
* Provide Salivary samples


Eligibility Criteria:
Inclusion Criteria:

* Structural Firefighter

Exclusion Criteria:

* • Participants have a cardiometabolic disease for which they take prescribed medications

  * Participants consume supplements known to impact hydration status or performance that they are not willing to stop taking for the study
  * Participants are pregnant
  * Female participants that have irregular menstrual cycles
  * Participants are injured and would not be able to fulfill the live burn scenario
  * Participants have sickle cell disease
  * Participants have experienced heat stroke within the last 2 years
Vivio AS (Aortic Stenosis) Algorithm Optimization Study

Optimize a candidate software algorithm using data collected with the Vivio system for use as an aid in the identification of heart sounds associated with severe aortic stenosis

Prospective, non-randomized, single-center study of adult subjects referred for echocardiography. Total of 200 enrolled subjects at 1 site

Enrolled subjects will undergo:

Vivio system data capture, standard of care transthoracic echocardiogram (TTE). Vivio analysis will not be available to non-Avicena personnel

Eligibility Criteria:
Inclusion Criteria:

1. Adult subjects (21 years of age or older).
2. Referred for transthoracic echocardiography by physician/primary care provider/cardiologist.
3. Willing and able to participate in all study evaluations and allow access to medical testing and records.
4. Ability to understand and sign an informed consent or have a legally authorized representative to provide informed consent on behalf of the subject.

Exclusion Criteria:

1. Acute coronary syndrome, cardiogenic shock or the need for inotropic/mechanical circulatory support.
2. Need for bedside echocardiogram (inpatient).
3. Prosthetic device previously implanted at aortic valve position.
4. Inability to palpate carotid pulse
5. History of carotid sinus hypersensitivity (i.e. fainting in response to touching or positioning the neck).
6. History of significant carotid artery disease or treatment (surgery, stenting, \> 50% stenosis in both left and right carotid artery).
7. Open skin lesions at target site of Vivio examination.
Postoperative Desogestrel for Endometriosis Related Pain

Endometriosis is one of the most common disease in reproductive aged women.Surgical intervention has a significant symptoms relief. However, symptom recurrence is often after surgery. This study aims to determine the efficacy of Desogestrel compared with placebo in pain symptom of symptomatic endometriosis patient undergo conservative surgery . The primary outcome measurement is pain score at 6 months after surgery.

After conservative surgery, the patients are randomized to Desogestrel and placebo groups. VAS pain score are compared after complete 6 months

Eligibility Criteria:
Inclusion Criteria:

* diagnoses endometriosis
* Plan conservative surgery
* initial pain score at least 5
* voluntary to be the participant of this study with inform consent
* No desired child bearing in 6 months

Exclusion Criteria:

* residual lesion after surgery which required further treatment
* cannot participate complete 6 months after surgery
* contraindication for Desogestrel, Paracetamol or Ponstan
* Pregnant
IU Health Krannert Personalized Medicine Study

Randomized controlled study to examine physician use of pharmacogenetic information in patients receiving antiplatelet medication after percutaneous coronary intervention (PCI).

The study will randomize patients who have completed PCI and who are prescribed dual antiplatelet therapy to a genotype guided arm, in which CYP2C19 pharmacogenetic testing will be performed and a standard therapy arm without genetic testing. The study will examine the impact of pharmacogenetic testing on physician medication choice and clinical outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Patients with ischemic heart disease, who are prescribed dual antiplatelet therapy after percutaneous coronary intervention (PCI). Enrollment has to occur during index hospitalization or during outpatient visit for cath lab procedure.

Exclusion Criteria:

* Pregnant or breastfeeding.
* Unwilling or unable, in the opinion of the investigator, to comply with instructions on prescribed medicines.
* Prior known allergy or intolerance to clopidogrel.
Next-generation Effects of Vitamin D Supplementation in Pregnancy

Vitamin D deficiency is common among pregnant women, despite daily vitamin D supplements. This study aims to investigate if maternal vitamin D intake of 90 vs 10 µg affects the overall health, growth, and immune system of the offspring at birth and after 1 year. Blood samples at birth and after one year, questionnaires and clinical 1-year examination will be performed on the children.

Vitamin D deficiency is common among Danish pregnant women, although most pregnant women adhere to guidelines of a daily supplement of 10 µg vitamin D. Vitamin D deficiency increases the risk of complications in the pregnancy e.g., preeclampsia, gestational diabetes mellitus and fetal growth retardation. Several studies indicate that the offspring has an increased risk of immune diseases e.g., asthma and autoimmune related diseases e.g., multiple sclerosis if the mother had vitamin D deficiency during the pregnancy. It is well known that vitamin D affects the immune system, which raises the question of the effects of vitamin D supplements and which doses to give optimally.

This study aims to investigate if maternal vitamin D intake of 90 vs 10 µg D3 affects the overall health, growth, and immune system of the offspring at birth and after 1 year. Blood samples at birth and after 1 year, questionnaires and clinical 1-year examination will be performed on the children. The hypothesis is that increased vitamin D supplementation in pregnancy improves fetal development including the offspring's immune system and the developing brain. The effects of vitamin D supplementation will strengthen the offspring's overall health at birth and during their first year of life. Hopefully, this can, in the future, be part of a guideline to which dose of vitamin D is recommended for Danish pregnant women.

Eligibility Criteria:
Inclusion Criteria:

* Born by mother from our previous RCT (NCT04291313)
* All with parental authority have given consent for inclusion

Exclusion Criteria:

* Mother with compliance \<80% to study drug
* Mother has denied further contact in this follow-up study
Extrapulmonary Interventional Ventilatory Support in Severe Acute Respiratory Distress Syndrome (ARDS)

A prospective, randomized study will be performed investigating the effects of a pumpless extracorporeal interventional lung assist \[iLA\] on the implementation of a lung-protective ventilatory strategy in patients with acute respiratory distress syndrome \[ARDS\] with a PaO2/FiO2 ratio \< 200. The duration of ventilation, intensive care and hospital stay and in-hospital mortality will be investigated.

Evaluation group:

Implantation of the iLA - adaptation of the ventilation strategy, explantation of the iLA after corresponding improvement (see treatment plan for details) - weaning from the ventilation and extubation according to specified criteria.

Control group:

Ventilation strategy based on the concept of lung-protective ventilation without extracorporeal support, weaning from the ventilation and extubation according to specified criteria (see treatment plan for details).

Eligibility Criteria:
Inclusion Criteria:

* The trial subjects are patients aged 18 years or older who have developed severe ARDS. Following the American-European Consensus Conference on ARDS, severe ARDS is defined as an oxygenation index (PaO2/FIO2) \< 200 mmHg. These parameters must be present for a duration of at least 2 hours.

Exclusion Criteria:

* age \< 18 years
* decompensated heart insufficiency
* acute coronary syndrome
* severe chronic obstructive pulmonary disease
* advanced tumour conditions with life expectancy \< 6 months
* chronic dialysis treatment
* lung transplant patients
* proven Heparin-induced thrombocytopenia (HIT)
* morbid obesity (BMI \>) 40
* Child Class B and C cirrhosis of the liver, acute fulminant hepatic failure
* severe peripheral arterial occlusive disease (pAVK III - IV), absence of limb doppler pulse
* brain injury (GCS \< 9 + CT pathology)